MDT

88.97

-0.32%↓

VEEV

280.11

-0.04%↓

A

114.58

+1.24%↑

WBA

11.51

0%↓

HQY

99.14

+2.32%↑

MDT

88.97

-0.32%↓

VEEV

280.11

-0.04%↓

A

114.58

+1.24%↑

WBA

11.51

0%↓

HQY

99.14

+2.32%↑

MDT

88.97

-0.32%↓

VEEV

280.11

-0.04%↓

A

114.58

+1.24%↑

WBA

11.51

0%↓

HQY

99.14

+2.32%↑

MDT

88.97

-0.32%↓

VEEV

280.11

-0.04%↓

A

114.58

+1.24%↑

WBA

11.51

0%↓

HQY

99.14

+2.32%↑

MDT

88.97

-0.32%↓

VEEV

280.11

-0.04%↓

A

114.58

+1.24%↑

WBA

11.51

0%↓

HQY

99.14

+2.32%↑

Search

ACADIA Pharmaceuticals Inc

Deschisă

SectorSănătate

23.05 3.97

Rezumat

Modificarea prețului

24h

Curent

Minim

21.89

Maxim

23.1

Indicatori cheie

By Trading Economics

Venit

-125M

19M

Vânzări

-15M

244M

P/E

Medie Sector

15.978

39.857

Marjă de profit

7.771

Angajați

653

EBITDA

7.1M

19M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+28.87% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

374M

3.7B

Deschiderea anterioară

19.08

Închiderea anterioară

23.05

Sentimentul știrilor

By Acuity

34%

66%

98 / 376 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

ACADIA Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

16 iul. 2025, 23:56 UTC

Achiziții, Fuziuni, Preluări

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- 2nd Update

16 iul. 2025, 23:43 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Output Rises 1% as Takeover Campaign Continues

16 iul. 2025, 23:00 UTC

Achiziții, Fuziuni, Preluări

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- Update

16 iul. 2025, 22:38 UTC

Achiziții, Fuziuni, Preluări

Alimentation Couche-Tard Withdraws Seven & i Acquisition Proposal

16 iul. 2025, 23:44 UTC

Market Talk

Gold Steady; Geopolitical Tensions in Middle East Support -- Market Talk

16 iul. 2025, 23:42 UTC

Market Talk

Nikkei May Fall as Yen Strengthens -- Market Talk

16 iul. 2025, 23:24 UTC

Market Talk

Australian Job Market Data to Shape RBA Calls -- Market Talk

16 iul. 2025, 23:18 UTC

Achiziții, Fuziuni, Preluări

Santos Now Expects 2025 Production of 90 Million-95 Million BOE

16 iul. 2025, 23:18 UTC

Achiziții, Fuziuni, Preluări

Santos Cuts Top End of 2025 Production Guidance

16 iul. 2025, 23:17 UTC

Achiziții, Fuziuni, Preluări

Santos: Production Recovery Underway in Cooper Basin

16 iul. 2025, 23:17 UTC

Achiziții, Fuziuni, Preluări

Santos: Over 200 Wells, Several Upstream Compressors in Cooper Basin Shut In

16 iul. 2025, 23:17 UTC

Achiziții, Fuziuni, Preluări

Santos: Cooper Basin Production Impacted by Floods in 2Q

16 iul. 2025, 23:16 UTC

Achiziții, Fuziuni, Preluări

Santos: Pikka Phase 1 Project in Alasia 89% Complete

16 iul. 2025, 23:16 UTC

Achiziții, Fuziuni, Preluări

Santos Keeps 2025 Major Development Project Capex Guidance Unchanged

16 iul. 2025, 23:13 UTC

Achiziții, Fuziuni, Preluări

Santos Had Gearing of 20.5% at End-June, Excluding Operating Leases

16 iul. 2025, 23:13 UTC

Achiziții, Fuziuni, Preluări

Santos Says Moomba CCS Phase 1 Project Performing to Expectations

16 iul. 2025, 23:12 UTC

Achiziții, Fuziuni, Preluări

Santos Narrows 2025 Unit Production Cost Guidance to US$7.00-US$7.40/BOE

16 iul. 2025, 23:12 UTC

Achiziții, Fuziuni, Preluări

Santos 1H Free Cash Flow From Operations US$1.1 Billion

16 iul. 2025, 23:11 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Free Cash Flow From Operations US$620 Million

16 iul. 2025, 23:11 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Oil, Natural Gas Output 22.2 Million BOE

16 iul. 2025, 23:11 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Oil, Natural Gas Sales Volumes 23.9 Million BOE

16 iul. 2025, 23:11 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Oil, Natural Gas Sales Volumes Up 3% on 1Q

16 iul. 2025, 23:11 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Oil, Natural Gas Output Up 1% on 1Q

16 iul. 2025, 22:43 UTC

Market Talk

Alcoa Using High Costs of More Production to Battle Tariff -- Market Talk

16 iul. 2025, 22:35 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

16 iul. 2025, 22:35 UTC

Market Talk
Câștiguri

Replacing Aluminum Imports With U.S. Production Not Seen Feasible -- Market Talk

16 iul. 2025, 22:33 UTC

Market Talk
Câștiguri

Alcoa Will Continue to Ship Aluminum Outside of the U.S. -- Market Talk

16 iul. 2025, 22:28 UTC

Market Talk
Câștiguri

Aluminum Price in U.S. Doesn't Offset Tariff Costs, Alcoa says -- Market Talk

16 iul. 2025, 22:22 UTC

Market Talk
Câștiguri

Market Talk Roundup: Latest on U.S. Politics

16 iul. 2025, 22:22 UTC

Market Talk
Câștiguri

Alcoa Considers Restart of Idle Capacity at Indiana Smelter -- Market Talk

Comparație

Modificare preț

ACADIA Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

28.87% sus

Prognoză pe 12 luni

Medie 29.06 USD  28.87%

Maxim 39 USD

Minim 15 USD

În baza a 19 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruACADIA Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

19 ratings

13

Cumpărare

5

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

14.845 / N/ASuport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Neutral Evidence

Sentiment

By Acuity

98 / 376 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.